Crescent Biopharma Stock Forecast

Stock Price Forecast

The 5 analysts that cover Crescent Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $25.6, which forecasts a 96.02% increase in the stock price over the next year. The lowest target is $22 and the highest is $28.

Price Target: $25.6 (+96.02%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$22	$25.6	$26	$28
Change	+68.45%	+96.02%	+99.08%	+114.40%

* Price targets were last updated on Aug 27, 2025.

Analyst Ratings

The average analyst rating for Crescent Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jun '25	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25
Strong Buy	1	1	3	3	3	3
Buy	1	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	3	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $25	Strong Buy	Reiterates	$25	+91.42%	Aug 27, 2025
Akash Tewari Jefferies	Jefferies	Strong Buy Initiates $26	Strong Buy	Initiates	$26	+99.08%	Aug 25, 2025
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $25	Strong Buy	Initiates	$25	+91.42%	Aug 11, 2025
Robert Driscoll Wedbush	Wedbush	Buy Initiates $27	Buy	Initiates	$27	+106.74%	Jul 14, 2025
Stephen Willey Stifel	Stifel	Strong Buy Initiates $28	Strong Buy	Initiates	$28	+114.40%	Jun 25, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-7.36

from -13.45

EPS Next Year

-5.55

from -7.36

Fiscal Year	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028	FY 2029
Period Ending	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028	Dec 31, 2029
Revenue	-	-	-	4.59M	6.12M	25.79M
Revenue Growth	-	-	-	-	33.33%	321.34%
EPS	-13.45	-7.36	-5.55	-7.46	-3.30	-4.61
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-
No. Analysts	-	8	8	7	4	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2025	2026
High	-6.30	-3.48
Avg	-7.36	-5.55
Low	-8.26	-10.30

EPS Growth

EPS Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.